Just like people, T cells get exhausted. Taking a break helps! Here, the authors developed a SNIP CAR - “a protease-based platform for regulating CAR activity using an FDA-approved small molecule”, which showed diminished T cell exhaustion bit.ly/3LgUqUr #Immunotherapy

How can regulatory T cells (Tregs) be depleted in cancer? In this recent paper in @ScienceTM, the authors show how dual targeting of CTLA4 and CD47 on Tregs is effective. bit.ly/3yT5DWd #AcademicTwitter #Immunotherapy @UTSWNews

What’s happening with CAR-T cells and beyond in cancer? This nice review summarizes recent advances and efforts to leverage T cells and NK cells. nature.com/articles/s41423-0… #Immunotherapy #AcademicTwitter

Can pre-treatment with targeted therapy influence response to subsequent immunotherapy? Here, they show that "when tumors relapse after anti-MAPK targeted therapy, they are cross-resistant to immunotherapies". nature.com/articles/s43018-0… #Immunotherapy @NatureCancer

Can immunotherapy provide long-term responses? Median survival (months) for metastatic melanoma was reported at ASCO for: CTLA4 + PD1 👉 72.1 PD1 👉 36.9 CTLA4 👉 19.9 #AcademicTwitter #cancer #Immunotherapy @ASCOPost ascopost.com/news/june-2021/…

Predicting response to immunotherapy is important, but what’s a good marker? Here they show how TCR clonality of tumor-infiltrating T cells predict anti-PD1 efficacy: nature.com/articles/s41467-0… #AcademicTwitter #cancer #immunotherapy @NatureComms

Does tumor location/tissue site matter? Here they show how the same tumor cell line display different take rates, immune infiltration, and response to immunotherapy depending on where the tumor grows. cancerimmunolres.aacrjournal… #AcademicTwitter #cancer #Immunotherapy @CIR_AACR

How do tumor cells survive in the circulation? This recent paper highlights the importance of CCL5 as a mediator of immune evasion. nature.com/articles/s41467-0… #AcademicTwitter #cancer @NatureComms

When to give immunotherapy? Giving anti-CTLA4 BEFORE anti-PD1 was found to be superior in this recent paper: go.nature.com/3w43rZL #AcademicTwitter #Immunotherapy @NatImmunol @ljiresearch

Who will respond to immunotherapy? This recent paper suggests that the tumor microenvironment falls into 4 categories and can predict therapeutic response: bit.ly/3wQDcXR #AcademicTwitter @MDAndersonNews @BostonGeneCorp